News

Logistics managers in life sciences and personal care focus on transportation capacity

First US biosimilar is hung up in litigation with Amgen; meanwhile, Amgen and others form a Biosimilars Forum and FDA issues some final biosimilar guidance

Combining high-quality patient-support services with comprehensive and continually updated analytics results in better outcomes

The growing number of certifications has become a competitive issue for SPPs bidding for Pharma's business

Meeting the compliance deadlines of the Drug Supply Chain Security Act has the attention of many in biopharma product and brand security

Streebo offers a free look at Sunshine Act data compiled by type, company and physician

IMS Institute report finds variations in access

As new cancer drugs with promising efficacy but brutal costs enter the market, providers, payers and manufacturers are strategizing new payment approaches

Heightened concern over adherence and product stability may win over more pharma clients

Mevion's compact S250 unit bids to change the economics of radiation oncology

Meanwhile, industry asset shuffling is at record levels

Obama's Precision Medicines initiative could re-open the door

Use of state-of-the-art software, combined with benchmarking and active oversight, fills this gap

Novo Nordisk is tagged as the only 'high performer'

Sandoz is first on the market with the MS drug, currently worth around $3 billion in the US

Effect of the first full year of Obamacare was muted, although a record number of prescriptions were written

Company targets evolving regenerative medicine market

$4.8-billion deal follows UPS' failed effort in 2013

Partners with EHR vendor PointClickCare to access 10,000 senior-care facilities in North America

Leading copay-coupon provider expands its patient services with private equity help

Service closes the loop on managing specialty-pharmaceutical therapy regimens

Do you know your J codes?

AstraZeneca's Seroquel XR sample kit takes top honors

If the count of working sales reps is rising, who will those reps be able to visit?

$12.8-billion acquisition will bring 1 billion precriptions/year under one PBM's management

Creation of a holding company streamlines future acquisitions; focus is on specialty drug services